Appointment of secretarial Auditors

Revenue growth above 20%Net loss reportedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹23.24

prior close

₹23.75

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-1.8% vs market

Pharmaceuticals peers, median of 150sector+0.2%-1.1% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.1

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0+0.8-1.8+0.2-1.1

Next day

-3.9+2.0-5.9+1.1-5.1

+2.8+0.9+1.9+0.1+2.7

-1.2+1.7-2.8+1.0-2.2

-3.1+1.6-4.7+1.2-4.3

+1.1+2.2-1.1+0.7+0.4

+1.1+2.7-1.6+1.4-0.3

15d

+4.3+4.5-0.2+0.6+3.7

+3.3+5.6-2.3+2.1+1.2

+21.3+9.0+12.4+3.8+17.5

+6.2+3.5+2.6-1.0+7.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unjha Formulations Ltd's board, at its meeting on May 16, 2025, approved the audited financial results for Q4 and full year ended March 31, 2025. Net sales from operations rose to about Rs. 1,849.6 lakh in FY25, up roughly 33% from Rs. 1,391.7 lakh in FY24. However, the company slipped deeper into losses, posting a net loss of around Rs. 40.76 lakh in FY25 versus Rs. 27.79 lakh in FY24, translating to a basic and diluted EPS of Rs. (0.91) versus Rs. (0.39) earlier. The statutory auditor (Jain & Golechha) issued an un-modified (clean) opinion with no key audit matters flagged. The board also appointed M/s Ajay Parikh & Associates, Practicing Company Secretaries, Ahmedabad, as the Secretarial Auditor for a five-year term covering FY26 to FY30, subject to shareholder approval.

Likely market impact

Top-line growth is encouraging for a small-cap pharma company, but persistent and widening losses mean this is unlikely to be a positive stock catalyst. The clean audit opinion and routine 5-year secretarial auditor appointment are neutral governance events with no immediate material impact on shareholders.